MoonLake Immunotherapeutics (MLTX) PE Ratio: History & Chart

Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.

The P/E ratio is N/A as of 2026-10-06T22:51:57.367Z.

Stored calculation inputs

Calculation as of: 2026-10-06T22:51:57.367Z.

Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.

Quote price: 10.95
Unrounded diluted TTM EPS · period ending 2026-06-30: -3.85

FMP input reference: 69a1d57d3f318828ebe19021960b74268097702d5d6050a421f3255bba496414

Forward PE Ratio|PEG Ratio|P/B Ratio|EPS|All Metrics

MLTX PE Ratio Metrics

PE RATIO

N/A

MLTX Competitors' PE Ratio

MLTX

MoonLake Immunotherapeutics

Current

Market Cap

$921.06M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CBLL

CeriBell, Inc.

vs MLTX

Market Cap

$923.53M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HSTM

HealthStream, Inc.

vs MLTX

Market Cap

$914.73M

PE Ratio

43.77

TTM Avg

37.03

3Y Avg

45.62

5Y Avg

62.08

SPTX

Seaport Therapeutics, Inc. Common Stock

vs MLTX

Market Cap

$929.83M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

KURA

Kura Oncology, Inc.

vs MLTX

Market Cap

$934.79M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SVRA

Savara Inc.

vs MLTX

Market Cap

$952.91M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AKTS

Aktis Oncology, Inc.

vs MLTX

Market Cap

$953.81M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CRVS

Corvus Pharmaceuticals, Inc.

vs MLTX

Market Cap

$887.99M

PE Ratio

N/A

TTM Avg

43.56

3Y Avg

43.56

5Y Avg

43.56

BVS

Bioventus Inc.

vs MLTX

Market Cap

$887.50M

PE Ratio

17.01

TTM Avg

40.25

3Y Avg

40.25

5Y Avg

34.02

ABUS

Arbutus Biopharma Corp

vs MLTX

Market Cap

$884.97M

PE Ratio

5.74

TTM Avg

5.80

3Y Avg

5.80

5Y Avg

5.80

NAME	MARKET CAP	PE RATIO	TTM	3Y	5Y
MoonLake Immunotherapeutics (MLTX)	$921.06M	N/A	N/A	N/A	N/A
CeriBell, Inc. (CBLL)vs ›	$923.53M	N/A	N/A	N/A	N/A
HealthStream, Inc. (HSTM)vs ›	$914.73M	43.77	37.03	45.62	62.08
Seaport Therapeutics, Inc. Common Stock (SPTX)vs ›	$929.83M	N/A	N/A	N/A	N/A
Kura Oncology, Inc. (KURA)vs ›	$934.79M	N/A	N/A	N/A	N/A
Savara Inc. (SVRA)vs ›	$952.91M	N/A	N/A	N/A	N/A
Aktis Oncology, Inc. (AKTS)vs ›	$953.81M	N/A	N/A	N/A	N/A
Corvus Pharmaceuticals, Inc. (CRVS)vs ›	$887.99M	N/A	43.56	43.56	43.56
Bioventus Inc. (BVS)vs ›	$887.50M	17.01	40.25	40.25	34.02
Arbutus Biopharma Corp (ABUS)vs ›	$884.97M	5.74	5.80	5.80	5.80

P/E Comparison

Trailing P/E

N/A

Forward P/E

N/A

Forward P/E Calculation

View All Analyst Estimates

Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.

Calculation:

Current Price

$10.95

÷

Forward EPS (Est.)

$-3.37

=

Forward P/E

N/A

Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.

PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

See the Lowest P/E Ratio Stocks ranking →

PE Ratio: N/A

MLTX PE Ratio Metrics

MLTX Competitors' PE Ratio

P/E Comparison

Forward P/E Calculation

PE Ratio Formula & Definition

Related Metrics